Security record · archived quarter
ABVX
Abivax S.A. · Healthcare · Biotechnology
4Tracked holders
-1Δ holders
2.69MShares held
$20.57MReported value
+0New positions
−1Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | +11 | 15.45M | $2.06B | +15 | −3 |
| Q1 2026 | 72 | -1 | 18.00M | $2.00B | +4 | −5 |
| Q4 2025 | 72 | +3 | 22.08M | $2.98B | +3 | n/a |
| Q3 2025 | 11 | +5 | 9.45M | $802.20M | +5 | n/a |
| Q2 2025 | 4 | -1 | 2.69M | $20.57M | n/a | −1 |
| Q1 2025 | 5 | 0 | 2.48M | $15.51M | +1 | −1 |
| Q4 2024 | 5 | -1 | 1.91M | $14.02M | +1 | −2 |
| Q3 2024 | 6 | +1 | 2.23M | $25.72M | +1 | n/a |
| Q2 2024 | 5 | n/a | 1.50M | $19.77M | n/a | n/a |
Who holds it · Q2 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 1.25M | -8.8% | $9.58M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 1.25M | +26.8% | $9.58M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 167.89K | +470.7% | $1.28M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 16.82K | +0.4% | $128,657 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $467,758 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 250 holders, 49.39M shares, $5.28B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2025 ·
Methodology ·
Get this via the API